Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Abraham Thomas, panellist at three US Food and Drug Administration (FDA) hearings on new potential anti-obesity agents last year, discusses the need for change in the agency's anti-obesity regulatory guidelines.
The US Food and Drug Administration approved slightly fewer new drugs than in recent years, and the industry's focus on specialty-care products continued to shine through.
